Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Predictors of Response to Biologics in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Cohort Study

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Wearing Occlusive Gloves Increases the Density of Staphylococcus aureus in Patients with Hand Eczema

    Research output: Contribution to journalJournal articleResearch

  2. Characterization of the Oral and Gut Microbiota in Patients with Psoriatic Diseases: A Systematic Review

    Research output: Contribution to journalReviewResearchpeer-review

  3. Risk of Anogenital Warts in Renal Transplant Recipients Compared with Immunocompetent Controls: A Cross-sectional Clinical Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Topical Zinc Oxide Assessed in Two Human Wound-healing Models

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Family burden of hospital-managed pediatric atopic dermatitis: A nationwide registry-based study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Reply to: "Comment on 'Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis'"

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Biomarkers of subclinical atherosclerosis in patients with psoriasis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Comparison of Cytokines in Skin Biopsies and Tape Strips from Adults with Atopic Dermatitis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Identifying patient characteristics associated with achieving treatment response to biologics in patients with psoriasis could prevent expensive switching between biologics. The aim of this study was to identify patient characteristics that predict the efficacy of treatment for biologics that inhibit tumour necrosis factor-α, interleukin-12/-23, and -17A. The study investigated biologic-naïve patients from the DERMBIO registry treated with adalimumab, etanercept, infliximab, secukinumab, or ustekinumab. Multivariable logistic models were conducted to assess associations between patient characteristics and treatment response. A total of 2,384 patients were included (adalimumab n = 911; etanercept n = 327; infliximab n = 152; secukinumab n = 323; ustekinumab n = 671). Smoking (odds ratio 0.74; 95% confidence interval (CI) 0.56-0.97; p = 0.03) and higher bodyweight (odds ratio 0.989; 95% CI 0.984-0.994; p < 0.001) reduced the odds of achieving response defined as Psoriasis Area and Severity Index ≤2.0 after 6 months of treatment. In conclusion, higher bodyweight and smoking were associated with a reduced probability of treatment response for tumour necrosis factor-α inhibitors, ustekinumab, and secukinumab.

Original languageEnglish
JournalActa Dermato-Venereologica
Volume101
Issue number10
Pages (from-to)adv00579
ISSN0001-5555
DOIs
Publication statusPublished - 26 Oct 2021

    Research areas

  • Adalimumab/therapeutic use, Biological Products/adverse effects, Cohort Studies, Denmark/epidemiology, Etanercept/therapeutic use, Humans, Psoriasis/diagnosis, Treatment Outcome, Ustekinumab/therapeutic use

ID: 69211337